Peru announces Sinopharm vaccine trial suspension following adverse event
The Peruvian government Saturday announced the suspension of trials for the Chinese Sinopharm vaccine against COVID-19 after a serious adverse event was recorded in one of the trial participants, according to Reuters.
In statements, the ministry of health said that the occurence is currently under investigation to detemine whether the serious reaction was related to the vaccine or otherwise, adding that the temporary suspension is merely a safety measure to ensure the health of the participants.
According to Reuters, the Chief Researcher at Cayetano Heredia University who is involved with the trial, said one volunteer had experienced weakening of his legs among other symptoms.
The Asian Herald
December 15, 2020
Source: Reuters
Peru suspends Chinese vaccine meant for Coronavirus. A major Chinese vaccine was at a trial phase. The decision came after a patient suffers serious neurological problems.
Read More );
}());
The Peruvian Health Minister Pilar Mazzetti said the decision was taken by the National Institute of Health (INS). The vaccine of Sinipharm was stopped to evaluate the adverse impact of the trial vaccine after the participant experienced neurological problems.
The Chief Researcher at Cayetano Heredia University, German Malaga, said that among many other symptoms, the participant has developed decreased strength in his legs. The vaccine was to complete the first phase in a few days. However, the authorities are now asserting whether the symptoms developed are from the vaccine or any other reason.